![Michael Cassano](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Michael Cassano
Antiguos cargos conocidos de Michael Cassano.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Director Técnico/Científico/I+D | 20/04/2009 | 18/08/2012 |
JOHN WILEY & SONS, INC. | Corporate Officer/Principal | - | - |
Formación de Michael Cassano.
University of Minnesota | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectorial
Consumer Services | 3 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
JOHN WILEY & SONS, INC. | Consumer Services |
Empresas privadas | 1 |
---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
- Bolsa de valores
- Insiders
- Michael Cassano
- Experiencia